Cancer’s Vulnerability is Our Strength
Cyteir is developing the next generation of synthetic lethal therapies to treat cancer.
Scientific Approach
Oncogenic transformations lead to DNA breaks that require repair for cancer cells to survive. This makes cancer cells vulnerable to targeted treatments that disrupt DNA damage response and repair. Cyteir treatments exploit this vulnerability by inducing synthetic lethality in tumor cells while sparing normal cells.
Cyteir’s Culture
With a pioneering spirit, putting patients first, we advance science passionately and collaboratively, in a fun learning environment. We value open, honest and transparent communication. We work diligently with respect for each other with a sense of urgency, integrity, accountability and purpose.
Recent News
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program
Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical Trials of Lead RAD51 Program Proceeds will support monotherapy and combination therapy trials of first-in-class RAD51 inhibitor CYT-0851, as well as fund [...]
Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Cyteir Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference LEXINGTON, Mass., January 7, 2021 – Cyteir Therapeutics, a leader in the discovery and development of next-generation synthetic lethal therapies to treat [...]
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team
Cyteir Therapeutics Advances Clinical Trial of Lead RAD51 Synthetic Lethality Program in Cancer and Expands Senior Leadership Team Phase 1/2 study of first-in-class inhibitor of RAD51-mediated homologous recombination advancing to once-daily dosing Secrist, Gengos [...]
“The development and approval of PARP inhibitors have paved the way for additional, novel DNA repair and synthetic lethality-based therapies to address unmet needs in cancer treatment.”
Markus Renschler, MD
President and Chief Executive Officer